Survival and clinical outcomes of kidney transplant recipients with coronavirus disease infection: An updated systematic review and meta-analysis

Made Dyah Vismita Indramila Duarsa1, Yenny Kandarini2, Niwanda Yogiswara3, Yudhistira Pradnyan Kloping3

Cite this article as: Duarsa MDVI, Kandarini Y, Yogiswara N, Kloping YP. Survival and clinical outcomes of kidney transplant recipients with coronavirus disease infection: An updated systematic review and meta-analysis. Turk J Urol. 2022; 48(1): 17-29

ABSTRACT

The recent outbreak of the 2019 novel coronavirus disease (COVID-19) has raised a tremendous global concern among people, especially those with pre-existing comorbidities. Kidney transplant (KT) recipients represent a susceptible category of patients due to the long-term administration of immunosuppressive therapy. However, data on how COVID-19 is affecting these patients are scarce. We aim to systematically review the current findings regarding survival and clinical outcomes of KT recipients with COVID-19 infection. A comprehensive literature search was conducted from PubMed and Embase published up to May 2021. Studies reporting data on the incidence of COVID-19 infection among KT recipients were included. The primary outcomes analyzed in this study, including mortality rate, mechanical ventilation requirement, intensive care unit (ICU) admission, and acute kidney injury (AKI) occurrence, were measured as a pooled prevalence rate (PR) with 95% confidence intervals (CIs). All analyses were performed using STATA® 16. A total of 30 studies comprising 3,146 KT recipients with COVID-19 infections were included. The pooled PR of mortality among KT recipients with COVID-19 infection was 21% (95% CI, 18% to 25%), ICU admission, 24% (95% CI, 20% to 28%), mechanical ventilation, 18% (95% CI, 15% to 21%), and AKI, 48% (95% CI, 42% to 53%). Meta-regression analysis showed that age was significantly associated with a higher mortality rate ($P < .01$). Mortality rate associated with age and relatively poor clinical outcomes were high among KT recipients with COVID-19 infection. Further studies addressing preventive measures for this at-risk population should be encouraged.

Keywords: COVID-19; kidney transplantation; SARS-CoV-2 infection; organ transplants.

Introduction

In December 2019, in Wuhan, China, a peculiar infection began spreading among people causing signs of pneumonia of unknown origin. Biological testing indicated that this pneumonia-like infection was caused by a novel coronavirus, which was officially referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1

As this pandemic continues to unfold, the data show wide variations in clinical characteristics down to outcomes. This COVID-19 occurred and spread throughout China. It continues to spread widely to various countries around the world.2 To date, there have been several recommendations for community-based health interventions from multiple organizations, and there is still much debate about the optimal COVID-19 treatment strategy.

The incidence of each individual causes various symptoms. Among them, patients with immunosuppressive conditions, especially the kidney transplant (KT) recipients focused on in this study, theoretically have a higher risk for developing critical COVID-19. This occurs because KT recipients are in a chronic

1 Graduated Medical Student of Udayana University Faculty of Medicine, Bali, Indonesia
2 Department of Internal Medicine, Sanglah General Hospital, Bali, Indonesia
3 Graduated Medical Student of Airlangga University Faculty of Medicine, Surabaya, Indonesia

Submitted: 29.04.2021
Accepted: 29.09.2021
Corresponding Author: Yenny Kandarini
E-mail: yenny_kandarini@unud.ac.id

© Copyright 2022 by Turkish Association of Urology
Available online at www.turkishjournalofurology.com
state of immunosuppression and comorbidity. The impact of chronic immunosuppression on clinical and survival outcomes of COVID-19 is currently unclear as there are only limited data on COVID-19 in transplant recipients.1,3 However, it is relevant since host inflammatory responses appear to constitute an important cause of poorly associated organ injury.3

Even though there is a great concern on the severity of clinical manifestations and the survival outcomes of COVID-19 in the KT recipient population, published reviews evaluating the results of studies regarding this phenomenon are still limited.4,5 Therefore, this study was made with the aim of assessing the survival and clinical outcome of transplant recipient patients with COVID-19 infection.

Material and Methods

This research followed the recommendations described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.6 Ethical approval was not required in this present study as its exclusive use of secondary data.

Eligibility Criteria

This review used population, intervention/exposure, comparison, and outcome (PICO) framework as summarized in Table 1. We considered eligible for the inclusion of cross-sectional, cohort, case series, and case–control studies evaluating in KT with positive swab test using real-time reverse transcription-polymerase chain reaction assay for SARS-CoV-2 reporting survival and clinical outcomes of the hospitalized patients. The exclusion criteria were (1) non-English articles, (2) study reported irrelevant outcomes to our interest, or the data could not be extracted; (3) animal studies and in vitro studies; and (4) conference papers, case-report, theses, and patents.

Table 1. Research Question

| PICO Component       | Description                                      |
|----------------------|--------------------------------------------------|
| Population           | Kidney transplant recipients aged more than 18 years |
| Intervention/exposure| Coronavirus disease 2019 (COVID-19)               |
| Comparison           | None                                             |
| Outcome              | Mortality, mechanical ventilation, AKI, ICU admission |

Main Points

- The pooled prevalence rate of mortality among kidney transplant recipients with COVID-19 infection was 21% (18% to 25%).
- Meta-regression analysis results showed that age was significantly associated with the rate of mortality.
- The pooled prevalence rate of acute kidney injury among kidney transplant recipients with COVID-19 infection was 48% (42% to 53%).

Literature Search and Study Selection

We conducted a comprehensive literature search using PubMed, Scopus, and Embase with the search period up to May 2021, using the following keywords: COVID-19 OR Coronavirus OR SARS-CoV-2 AND Kidney Transplant recipient OR Renal Transplant recipient OR Kidney Transplantation OR Renal Transplantation. Titles and abstracts taken from database searches were screened independently by three authors (M.D.V.I.D., N.Y., and Y.P.K.) to assess their potential eligibility to be included. Relevant articles were examined in full-text for eligibility criteria. Any disagreements were resolved by evaluating the full-text articles and discussion with senior authors (Y.K.). We demonstrated the process of study search and selection in a search flow diagram.

Data Collection and Quality Assessment

To ensure standardization of data extraction from the included articles, we used piloted data extraction forms. The data collected included (1) author, (2) location of the study, (3) design of the study, (4) number of participants, (5) average age of participant, (6) time on KT, and (7) percentage of men. The primary endpoints were the prevalence of mortality, mechanical ventilation, ICU admission, and AKI. The quality assessment was performed utilizing the Newcastle-Ottawa Scale, which evaluated the selection, comparability, and outcome of the included studies.7 We further reported the pooled prevalence with 95% confidence intervals (CIs) for studies. All data were recorded into a database manager, Microsoft Excel 2019.

Data Analysis

The data were pooled as weighted prevalence with 95% CI for the majority of a clinical outcome. We used the random-effect model if there was high heterogeneity found using the Chi-squared test and I² statistic. High heterogeneity was described by P-value ≤ .1 in the Chi-squared test and I² statistic > 50%.8 Otherwise, we used the fixed-effects Mantel–Haenszel model if there was low heterogeneity (P-value > .1 or I² statistic ≤ 50%). To determine the influence of study-level covariates on the effect estimate and heterogeneity, we performed univariate random-effects meta-regression with restricted maximum likelihood method using age, male gender, and time on kidney.
transplantation as the covariate. If \( P \) -value < .05, we consider the difference to have statistical significance. To assess the small-study effects, we used the Egger’s regression test with a graphical funnel plot. Stata version 16.0 (StataCorp LLC, Texas, United States) was used for data analysis.

**Results**

**Study Search and Characteristics**

The study selection process was summarized in Figure 1. From the multiple database searching, we identified a total of 1,448 records. After removing the duplication, we screened 1,297 abstracts and included 30 eligible studies for the meta-analysis. The majority of the study design was cohort with less than 100 patients. Studies were reported from multiple regions of the world, but most of them reported from Spain. The baseline characteristics and the quality assessment of the included studies were summarized in Tables 2 and 3, respectively. Studies reported similar characteristics regardless of their study location, the average age of the patients was 57 years old, and most patients were male (64.5%). Overall, the quality of the included studies was moderate, as displayed in Table 3.

**Survival and Clinical Outcome**

Prevalence rates for mortality were reported in 30 studies that included 3,146 patients. The pooled prevalence rate of mortality was 21% (95% CI, 18% to 25%). The forest plot displayed in Figure 2 revealed that the \( I^2 \) index was high among the studies (76.9%). Pooled analysis in Figure 3 showed that the ICU admission rate was 24% (95% CI, 20% to 28%) with substantial heterogeneity (\( I^2 = 73.4\% \)). The need for mechanical ventilation rate was 18% (95% CI, 15% to 21%) with observed high heterogeneity (\( I^2 = 70.94\% \)) as presented in Figure 4. The rate of AKI was 48% (95% CI, 42% to 53%, \( I^2 = 67.6\% \)), summarized in Figure 5.

---

Figure 1. PRISMA flow diagram.
Table 2. Baseline Characteristic of the Included Studies

| Author         | Country   | Study Design     | Hospitalized Patient, n | Age (year) | Time on KT (Months) | Men (%) | COVID-19 Therapeutic Management                                                                 | Primary endpoints Analyzed                                      |
|----------------|-----------|------------------|-------------------------|------------|---------------------|---------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Arenas et al.10| Spain     | Prospective cohort | 26                      | 70.3       | 73                  | 71.4    | Hydroxychloroquine, ceftriaxone, azithromycin, lopinavir/ritonavir, tocilizumab, steroids, enoxaparin | Mortality rate, ventilation rate, ICU admission rate                                                             |
| Columbia University11 | United States | Case series | 15                       | 51         | 49                  | 77      | Hydroxychloroquine, azithromycin                                                                 | Mortality rate, ventilation rate, AKI rate                                                                      |
| Crespo et al.22| Spain     | Prospective cohort | 16                      | 73.6       | 49                  | 75      | Hydroxychloroquine, darunavir/ritonavir, tocilizumab, steroids                                      | Mortality rate, ventilation rate, AKI rate, ICU admission rate                                                  |
| Devresse et al.33 | Belgium     | Case series | 18                       | 57         | 89                  | 44      | Hydroxychloroquine, steroids                                                                       | Mortality rate, ventilation rate, ICU admission rate                                                              |
| Elias et al.34 | France    | Prospective cohort | 66                      | 56.4       | 57.8                | 56      | Hydroxychloroquine, tocilizumab, eculizumab                                                         | Mortality rate, ventilation rate, AKI rate                                                                      |
| Rahbar et al.35 | Iran      | Prospective cohort | 19                      | 47.6       | NR                  | 68.4    | Hydroxychloroquine, ribavirin, lopinavir/ritonavir, IVIG, oseltamivir                               | Mortality rate, ventilation rate, AKI rate, ICU admission rate                                                  |
| Alberici et al.36 | Italy     | Case series | 20                       | 59         | 156                 | 75      | Hydroxychloroquine, lopinavir/ritonavir, dexamethasone, tocilizumab, darunavir/ritonavir          | Mortality rate, AKI rate, ICU admission rate                                                                   |
| Chen et al.37  | United States | Retrospective cohort | 30                      | 56         | 84                  | 53      | Hydroxychloroquine + azithromycin                                                                  | Mortality rate, ventilation rate                                                                                  |
| Fava et al.38  | Spain     | Retrospective cohort | 104                     | 59.7       | 59                  | 55.7    | Hydroxychloroquine, remdesivir, tocilizumab, lopinavir/ritonavir, ifn-β, darunavir/ cobicistat, darunavir/ritonavir | Mortality rate, ventilation rate, AKI rate, ICU admission rate                                                  |
| Lubetsky et al.39 | United States | Case series | 39                       | 57         | NR                  | 70      | Hydroxychloroquine, remdesivir, azithromycin, convalescent plasma, doxycycline, il-6 receptor inhibitor | Mortality rate, ventilation rate, AKI rate                                                                       |
| Pascual et al.13| Spain     | Case series | 24                       | 66.5       | 1                   | 46      | Hydroxychloroquine, glucocorticoids, tocilizumab, lopinavir/ritonavir                              | Mortality rate, ventilation rate                                                                                  |
| Al Oltaibi et al.12 | Kuwait     | Retrospective cohort | 82                       | 49.3       | 72                  | 76      | Low molecular weight heparin, antibiotics                                                           | Mortality rate, ventilation rate, ICU admission rate                                                              |
| Author                     | Country      | Study Design | Hospitalized Patient, n | Age  (year) | Time on KT (Months) | Men (%) | COVID-19 Therapeutic Management                                                                                                      | Primary endpoints Analyzed                                      |
|----------------------------|--------------|--------------|-------------------------|------------|--------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Benotmane et al.            | France       | Retrospective cohort | 41                      | 63.9       | 86.4               | 78      | Hydroxychloroquine, lopinavir/ritonavir, tocolizumab, azithromycin, corticosteroids                                            | Mortality rate, ventilation rate, AKI rate, ICU admission rate   |
| Bodro et al.                | Spain        | Retrospective cohort | 33                      | 55         | 66                 | 61      | Hydroxychloroquine, lopinavir/ritonavir, azithromycin, steroids                                                               | Mortality rate, ventilation rate, ICU admission rate             |
| Bruno et al.                | Italy        | Retrospective cohort | 11                      | 59.2       | 113.5              | 72.7    | Hydroxychloroquine, darunavir/ritonavir, lopinavir/ritonavir, azithromycin, tocilizumab                                    | Mortality rate, ventilation rate                                |
| Caillard et al.             | France       | Retrospective cohort | 273                     | 62         | 74.6               | 66.3    | Hydroxychloroquine, azithromycin, remdesivir, lopinavir/ritonavir, oseltamivir, tocilizumab                                 | Mortality rate, ventilation rate, ICU admission rate            |
| Chavarot et al.             | France       | Retrospective cohort | 100                     | 64.7       | 61.2               | 64      | Hydroxychloroquine, azithromycin, tocilizumab                                                                              | Mortality rate, ventilation rate, ICU admission rate            |
| Coll et al.                 | Spain        | Case series   | 375                     | 62         | 66                 | 65      | Hydroxychloroquine, azithromycin, protease inhibitor, IFN- β                                                              | Mortality rate, ventilation rate, ICU admission rate            |
| Craig-Schapiro et al.       | United States | Retrospective cohort | 52                      | 57         | 56.4               | 70      | Hydroxychloroquine, remdesivir, tocilizumab, convalescent plasma                                                             | Mortality rate, ventilation rate, AKI rate                       |
| Dheir et al.                | Turkey       | Cross-sectional | 20                      | 48         | 71.9               | 70      | Favipiravir, hydroxychloroquine, dexamethasone, oseltamivir, convalescent plasma, antibiotics                             | Mortality rate, ventilation rate, AKI rate                       |
| Georgery et al.             | Belgium      | Cohort        | 45                      | 60         | 93                 | 53      | Hydroxychloroquine, dexamethasone                                                                                            | Mortality rate, ICU rate                                        |
| Hillbrands et al.           | Multicentre  | Prospective cohort | 271                     | 60         | NR                 | 62      | Hydroxychloroquine, lopinavir/ritonavir, remdesivir, IFN, tocilizumab, steroids                                             | Mortality rate, ventilation rate, ICU admission rate            |
| Kute et al.                 | India        | Retrospective cohort | 250                     | 43         | 42                 | 86      | Hydroxychloroquine, azithromycin, tocilizumab, favipiravir, remdesivir, convalescent plasma, IVIG                        | Mortality rate, ventilation rate, AKI rate, ICU admission rate   |
| Mamode et al.               | United Kingdom | Retrospective cohort | 121                     | 56.2       | 79                 | 63      | Hydrocortisone, tocilizumab                                                                                                | Mortality rate, ventilation rate, ICU admission rate            |
Publication Bias
Visual inspection of the funnel plot appears to be qualitatively symmetrical, as shown in Figure 6, which demonstrates no evidence of publication bias. Further results for Egger’s test showed no evidence of small-study effects ($P = .186$).

Meta-Regression
Meta-regression analysis results showed that age was significantly associated with the rate of mortality ($P < .01$) (Figure 7). However, no significant association was observed for male gender ($P = .825$) and time on kidney transplantation ($P = .655$).

Discussion
This study provided the updated systematic review and meta-analysis of the survival and clinical outcomes of kidney transplants with COVID-19 infection compared to the previously published systematic review, which evaluated 15 studies. Preliminary reports suggested good clinical outcomes in renal patients with COVID-19 infection. However, recent studies have reported that this susceptible category population had a higher mortality rate than observed in the general population. Many studies hypothesized that immunosuppression may represent additional risk factors, although specific studies are still limited. Even though the patients had immunosuppression, the symptoms of kidney transplant recipients with COVID-19 infection were reported similar to the general population, including fever, dry cough, and dyspnea.

The global mortality rate from COVID-19 on the general population ranged from 0.7% to 10.8%, varied widely based on the location of the study. In Spain, 18 solid organ transplant...
(SOT) recipients diagnosed with COVID-19 had a mortality rate of 28%. In this review, we observed a lower mortality rate from 30 studies comprising 3,146 kidney transplants with COVID-19, with a rate of 21% (18% to 25%). This result was similar to the study focused on SOT recipients diagnosed with COVID-19. Pascual et al. reported in their study that the fatality rate during the first 60 days after kidney transplantation was considerably higher than the mortality found outside the pandemic of COVID-19. Our meta-regression analysis reported a significant association of age with mortality, but not male gender and time on KT. This result is consistent with previous studies demonstrating mortality from COVID-19 is highly associated with age, and the age of admitted patients is likely to have a consequential impact on mortality.

Even though our analysis did not show a significant association between mortality and time of KT, this variable might affect disease severity. In the first months after transplantation, the full impact of immunosuppression is exerted, which leads the recipients to be at maximum risk of viral infection and severity

| Study                  | Selection | Comparability | Outcome | Score |
|------------------------|-----------|---------------|---------|-------|
| Arenas et al.          | 1 ++ ++ ++ + | - - | + + - | ★★★★★★ |
| Columbia University    | - + + + + | - - | + - + | ★★★★★ |
| Crespo et al.          | - + + + + | - - | + + + | ★★★★★★ |
| Devresse et al.        | + + + + + | - - | + - - | ★★★★★ |
| Elias et al.           | + + + + + | - - | + + + | ★★★★★★ |
| Rahbar et al.          | - + + + + | - - | + + + | ★★★★★★ |
| Alberici et al.        | + - + + + | - - | + + + | ★★★★★★ |
| Chen et al.            | + - + + + | - - | + + + | ★★★★★★ |
| Fava et al.            | + + + + + | - - | + - + | ★★★★★★ |
| Lubetsky et al.        | + - + + + | - - | + + + | ★★★★★★ |
| Pascual et al.         | + - + + + | - - | + - - | ★★★★★ |
| Al Oltaibi et al.      | + + + + + | - - | + + + | ★★★★★★ |
| Benotmane et al.       | + + + + + | - - | + + + | ★★★★★★ |
| Bodro et al.           | + + + + + | - - | + - + | ★★★★★★ |
| Bruno et al.           | - + + + + | - - | + + + | ★★★★★★ |
| Caillard et al.        | + + + + + | - - | + + + | ★★★★★★★ |
| Chavarot et al.        | + + + + + | - - | + - + | ★★★★★★ |
| Coll et al.            | + + + + + | - - | + + + | ★★★★★★ |
| Craig-Schapiro et al.  | + + + + + | + - | + + + | ★★★★★★ |
| Dheir et al.           | + + + + + | - - | + - - | ★★★★★★ |
| Georgery et al.        | + + + + + | - - | + + + | ★★★★★★ |
| Hillbrands et al.      | + + + + + | + + | + + + | ★★★★★★★ |
| Kute et al.            | + + + + + | - - | + + + | ★★★★★★ |
| Mamode et al.          | + + + + + | - - | + - - | ★★★★★ |
| Oto et al.             | + + + + + | - - | + + - | ★★★★★ |
| Ozturk et al.          | + + + + + | - - | + + + | ★★★★★★ |
| Pierotti et al.        | + + + + + | - - | + + + | ★★★★★★ |
| Santeusanio et al.     | + + + + + | - - | + + + | ★★★★★★ |
| Tejada et al.          | + + + + + | - - | + - - | ★★★★★ |
| Villanego et al.       | + + + + + | - - | + + + | ★★★★★ |

Table 3. Risk of Bias Assessment Using Newcastle-Ottawa Scale
during this period.\textsuperscript{42} The ICU admission rate from six studies was 21% (10-31%), comparable to the results of a meta-analysis of 37 studies focusing on ICU admission rate in the general population (26%).\textsuperscript{46} However, this result could be biased because a study by Pascual et al\textsuperscript{42} reported some patients with the indication for ICU refuse to be admitted. The rate of mechanical ventilation requirement among kidney transplant recipients with COVID-19 was also higher than the general population (19% vs 3.5%, respectively).

Kidney injury in COVID-19 infection was suggested to be caused indirectly by the cytokine storm.\textsuperscript{37} However, Lubetzky et al\textsuperscript{39} hypothesized that COVID-19 might directly affect the kidney as the SARS-CoV-2 found in the kidney and urine. A meta-analysis of 20 studies focusing on AKI incidence in the general population infected with COVID-19 showed an incidence rate of 8.9% (4.6% to 14.5%).\textsuperscript{47} Our findings demonstrated a considerably higher incidence of AKI than the general population, with a rate of 44% (35% to 53%). Lubetzky et al\textsuperscript{39} proposed the potential explanation for the higher incidence of AKI in kidney transplant recipients with COVID-19. First, the recipients already have baseline stage 2 or 3 Chronic Kidney Disease (CKD) before the infection. Second, elevated tacrolimus trough level has been observed at admission in some patients, which may have further aggravated AKI.\textsuperscript{39}

This research has a few limitations. First, most studies were conducted with relatively small sample size and a short follow-up period, which resulted in limited insight. Second, studies reported limited data on baseline characteristics that were not enough observation to be further analyzed. Third, studies reported varied therapeutic management, which resulted in
Figure 3. Pooled estimate on mechanical ventilation rate of kidney transplant recipients with COVID-19 infection.
Figure 4. Pooled estimate on ICU admission rate of kidney transplant recipients with COVID-19 infection.
| Study                  | ES (95% CI) | Weight |
|-----------------------|-------------|--------|
| Columbia University (2020) | 0.40 (0.16, 0.68) | 3.36   |
| Crespo et al. (2020)   | 0.31 (0.11, 0.59) | 3.78   |
| Elias et al. (2020)    | 0.42 (0.30, 0.55) | 7.11   |
| Rahbar et al. (2020)   | 0.74 (0.49, 0.91) | 4.47   |
| Aherci et al. (2020)   | 0.30 (0.12, 0.54) | 4.40   |
| Fava et al. (2020)     | 0.47 (0.37, 0.57) | 8.06   |
| Lubetsky et al. (2020) | 0.51 (0.35, 0.68) | 5.71   |
| Al'Ottaibi et al. (2021) | 0.37 (0.26, 0.48) | 7.72   |
| Benotmane (2021)       | 0.76 (0.60, 0.88) | 6.63   |
| Caillard et al. (2021) | 0.46 (0.40, 0.52) | 9.52   |
| Craig-Schapiro et al. (2020) | 0.48 (0.34, 0.62) | 6.47   |
| Dheir et al. (2021)    | 0.25 (0.09, 0.49) | 4.70   |
| Kute et al. (2021)     | 0.48 (0.42, 0.55) | 9.42   |
| Oto et al. (2021)      | 0.42 (0.33, 0.52) | 8.20   |
| Santeusiano et al. (2021) | 0.58 (0.41, 0.74) | 5.71   |
| Tejada et al. (2020)   | 0.64 (0.43, 0.82) | 4.74   |
| Overall (I² = 67.61%, p = 0.00) | 0.48 (0.42, 0.53) | 100.00 |

Figure 5. Pooled estimate on AKI rate of kidney transplant recipients with COVID-19 infection.

Figure 6. Funnel plot for mortality of kidney transplant recipients with COVID-19 infection.

Figure 7. Meta-regression analysis on mortality rate of kidney transplant recipients with COVID-19 infection using age as moderator.
different clinical outcomes and produced considerable heterogeneity. The results of the studies, in general, show relatively higher mortality and poor clinical outcomes among kidney transplant recipients with COVID-19 infection. Therefore, preventive measures and adaptive treatment trials are urgently needed for this population.

**Conclusion**

The mortality rate associated with age and relatively poor clinical outcomes were high among kidney transplant recipients compared to general population with COVID-19 infection. Further studies addressing preventive measures for this at-risk population should be encouraged.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - M.D.V.I.D., Y.K.; Design - M.D.V.I.D., Y.K.; Supervision - Y.K.; Materials - M.D.V.I.D., N.Y., Y.P.K.; Data Collection and/or Processing - M.D.V.I.D., N.Y., Y.P.K.; Analysis and/or Interpretation - N.Y., Y.P.K.; Literature Search - M.D.V.I.D., N.Y., Y.P.K.; Writing Manuscript - M.D.V.I.D., Y.K., N.Y., Y.P.K.; Critical Review - M.D.V.I.D., Y.K.

**Conflict of Interest:** The authors have no conflicts of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-733. [CrossRef]
2. World Health Organization. World Health Organization coronavirus disease 2019 (COVID-19) situation report. 2020.
3. Guillen E, Pinoeiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? *Am J Transplant*. 2020;20:1875-1878. [CrossRef]
4. Mahalingaiai V, Craik A, Tomlinson LA, et al. A systematic review of COVID-19 and kidney transplantation. *Kidney Int Rep*. 2021;6(1):24-45. [CrossRef]
5. Phanish M, Ster IC, Ghazanfar A, et al. Systematic review and meta-analysis of COVID-19 and kidney transplant recipients, the South West London Kidney Transplant Network Experience. *Kidney Int Rep*. 2021;6(3):574-585. [CrossRef]
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ*. 2009;339:b2535. [CrossRef]
7. Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. 2015. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp
8. Higgins JPT, Thompson SGS. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558. [CrossRef]
9. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634. [CrossRef]
10. Arenas MD, Crespo M, Pérez-Sáez MJ, et al. Clinical profiles in renal patients with COVID-19. *J Clin Med*. 2020;9(8):2665. [CrossRef]
11. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. *J Am Soc Nephrol*. 2020;31(5):1150-1156.
12. Alotaibi TM, Gheith OA, Abuelmagd MM, et al. Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. *Clin Transplant*. 2021;35(6):e14297. [CrossRef]
13. Pascual J, Crespo M, Melilli E, et al. COVID-19-related mortality during the first 60 days after kidney transplantation. *Eur Urol*. 2020;78(4):641-643. [CrossRef]
14. Benotmane I, Perrin P, Vargas GG, et al. Biomarkers of cytokine release syndrome predict disease severity and mortality from COVID-19 in kidney transplant recipients. *Transplantation*. 2021;105(1):158-169. [CrossRef]
15. Bodo M, Herrera S, Linares L., et al. Use of anti-cytokine therapy in kidney transplant recipients with COVID-19. *J Clin Med*. 2021;10(8):1551. [CrossRef]
16. Bruno PF, Cappuccilli M, Spazzoli A, et al. COVID-19 infection: Viral clearance and antibody response in dialysis patients and renal transplant recipients. *Nephron*. 2021;145:1-8. [CrossRef]
17. Caillard S, Moulin B, Benotmane I, et al. Is COVID-19 infection more severe in kidney transplant recipients? *Am J Transplant*. 2021;21(3):1295-1303. [CrossRef]
18. Chavarot N, Gueguen J, Bonnet G, et al. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. *Am J Transplant*. 2021;21(3):1285-1294. [CrossRef]
19. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant*. 2020;21(5):1825-1837. [CrossRef]
20. Craig-Schapiro R, Salinas T, Lubetzky M, et al. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. *Am J Transplant*. 2021;21(4):1576-1585. [CrossRef]
21. Dheir H, Sipahi S, Yaylaci S, et al. Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. *Turkish J Med Sci*. 2021;51(2):428-434. [CrossRef]
22. Crespo M, Pérez-Sáez MJ, Redondo-Pachón D, et al. COVID-19 in elderly kidney transplant recipients. *Am J Transplant*. 2020;20(10):2883-2889. [CrossRef]
23. Geogery HH, Devresse A, Goffin E, et al. The second wave of COVID-19 disease in a kidney transplant recipient cohort: A single-center experience in Belgium. *Transplantation*. 2021;105(3):E41-E42. [CrossRef]
24. Hilbrands LB, Duivenvoorden RR, Vatt P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration. *Nephrol Dial Transplant*. 2020;35(11):1973-1983. [CrossRef]
25. Kute VB, Bhalla AK, Guleria S, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: A multi-center cohort study from India. *Transplantation*. 2021;105(4):851-860. [CrossRef]
26. Mamode N, Ahmed Z, Jones G, et al. Mortality rates in transplant recipients and transplantation candidates in a high-prevalence COVID-19 environment. *Transplantation*. 2021;105(1):212-215. [CrossRef]
27. Oto OA, Ozturk S, Turgutalp K, et al. Predicting the outcome of COVID-19 infection in kidney transplant recipients. *BMC Nephrol*. 2021;22(1):100. [CrossRef]
28. Ozturk S, Cebeci E, Turgutalp K, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: A nationwide analysis from Turkey. *Nephrol Dial Transplant*. 2021;35(12):2083-2095. [CrossRef]

29. Pierrotti LC, Reusing Junior JO, Freire MP, et al. COVID-19 among kidney-transplant recipients requiring hospitalization: Preliminary data and outcomes from a single-center in Brazil. *Transpl Int*. 2020;33(12):1837-1842. [CrossRef]

30. Santeusanio AD, Menon MC, Liu C, et al. Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). *Clin Transplant*. 2021;35(4):e14221. [CrossRef]

31. Jarrin Tejada CD, Zachariah M, Cruz ABV, et al. Favorable outcome of COVID-19 among African American (AA) renal transplant recipients in Detroit. *Clin Transplant*. 2021;35(2):e14169. [CrossRef]

32. Villanego F, Mazuecos A, Perez-Flores IM, et al. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. *Am J Transplant*. 2021;21(7):2573-2582. [CrossRef]

33. Devresse A, Belkhir L, Vo B, et al. COVID-19 infection in kidney transplant recipients: A single-center case series of 22 cases from Belgium. *Kidney Med*. 2020;2(4):459-466. [CrossRef]

34. Elias M, Pievani D, Randoux C, et al. COVID-19 infection in kidney transplant recipients: Disease incidence and clinical outcomes. *J Am Soc Nephrol*. 2020;31(10):2413-2423. [CrossRef]

35. Ghaffari Rahbar M, Nafar M, Khoshdel A, et al. Low rate of COVID-19 pneumonia in kidney transplant recipients—A battle between infection and immune response? *Transpl Infect Dis*. 2020;22(5):e13406. [CrossRef]

36. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney Int*. 2020;97(6):1083-1088. [CrossRef]

37. Chen TY, Farghaly S, Cham S, et al. COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. *Transpl Infect Dis*. 2020;22(5):e13378. [CrossRef]

38. Fava A, Cucchiari D, Montero N, et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. *Am J Transplant*. 2020;20(11):3030-3041. [CrossRef]

39. Lubetzky M, Aull MJ, Craig-Schapiro R, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: A report of consecutive cases from a New York City transplant center. *Nephrol Dial Transplant*. 2020;35(7):1250-1261. [CrossRef]

40. Mohan S. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. *J Am Soc Nephrol*. 2020;31(5):1150-1156.

41. Lubetzky M, Aull MJ, Craig-Schapiro R, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: A report of consecutive cases from a New York City transplant center. *Nephrol Dial Transplant*. 2020;35(7):1250-1261. [CrossRef]

42. Pascual J, Melilli E, Jiménez-Martín C, et al. COVID-19-related mortality during the first 60 days after kidney transplantation. *Eur Urol*. 2020;78(4):641-643. [CrossRef]

43. Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US: A clinical update. *JAMA*. 2020;323(18):1767-1768. [CrossRef]

44. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant*. 2020;20(7):1849-1858. [CrossRef]

45. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: A systematic review and meta-analysis of observational studies. *Anaesthesia*. 2020;75(10):1340-1349. [CrossRef]

46. Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of intensive care unit admission and outcomes among patients with coronavirus: A systematic review and meta-analysis. *PLoS One*. 2020;15(7):e0235653. [CrossRef]

47. Chen Y-T, Hsu C-K, Shao S-C, Wu I-W, Hung M-J, Chen Y-C. Incidence of acute kidney injury in COVID-19 infection: A systematic review and meta-analysis. *Crit Care*. 2020;24(1):346. [CrossRef]

48. Benotmane I, Gautier-Vargas G, Wendling MJ, et al. In-depth virological assessment of kidney transplant recipients with COVID-19. *Am J Transplant*. 2020;20(11):3162-3172. [CrossRef]

49. Caillard S, Thaunat O, Sophie H. Covid-19 in kidney transplantation: Lessons from the French registry. *Nephrol Ther*. 2021;17(4):233-244.

50. Chavarot N, Leruez-Ville M, Scemla A, et al. Decline and loss of anti–SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. *Kidney Int*. 2021;99(2):486-488. [CrossRef]

51. Santeusanio AD, Bhansali A, Rana M, Lerner S, Shapiro R, Rana AD. Kidney transplantation in patients with prior coronavirus disease 2019 (COVID-19). *Clin Transplant*. 2021;35(6):e14288. [CrossRef]